0001582982 false --12-31 Q2 0001582982 2023-01-01 2023-06-30 0001582982 CCLD:CommonStockParValue0.001PerShareMember 2023-01-01 2023-06-30 0001582982 CCLD:Sec11SeriesCumulativeRedeemablePerpetualPreferredStockParValue0.001PerShareMember 2023-01-01 2023-06-30 0001582982 CCLD:Sec8.75SeriesBCumulativeRedeemablePerpetualPreferredStockParValue0.001PerShareMember 2023-01-01 2023-06-30 0001582982 2023-07-30 0001582982 2023-06-30 0001582982 2022-12-31 0001582982 us-gaap:RelatedPartyMember 2023-06-30 0001582982 us-gaap:RelatedPartyMember 2022-12-31 0001582982 us-gaap:SeriesAPreferredStockMember 2023-06-30 0001582982 us-gaap:SeriesAPreferredStockMember 2022-12-31 0001582982 us-gaap:SeriesBPreferredStockMember 2023-06-30 0001582982 us-gaap:SeriesBPreferredStockMember 2022-12-31 0001582982 2023-04-01 2023-06-30 0001582982 2022-04-01 2022-06-30 0001582982 2022-01-01 2022-06-30 0001582982 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-12-31 0001582982 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2022-12-31 0001582982 us-gaap:CommonStockMember 2022-12-31 0001582982 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001582982 us-gaap:RetainedEarningsMember 2022-12-31 0001582982 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001582982 us-gaap:TreasuryStockCommonMember 2022-12-31 0001582982 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2023-03-31 0001582982 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2023-03-31 0001582982 us-gaap:CommonStockMember 2023-03-31 0001582982 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001582982 us-gaap:RetainedEarningsMember 2023-03-31 0001582982 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001582982 us-gaap:TreasuryStockCommonMember 2023-03-31 0001582982 2023-03-31 0001582982 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2021-12-31 0001582982 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2021-12-31 0001582982 us-gaap:CommonStockMember 2021-12-31 0001582982 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001582982 us-gaap:RetainedEarningsMember 2021-12-31 0001582982 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001582982 us-gaap:TreasuryStockCommonMember 2021-12-31 0001582982 2021-12-31 0001582982 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-03-31 0001582982 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2022-03-31 0001582982 us-gaap:CommonStockMember 2022-03-31 0001582982 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001582982 us-gaap:RetainedEarningsMember 2022-03-31 0001582982 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001582982 us-gaap:TreasuryStockCommonMember 2022-03-31 0001582982 2022-03-31 0001582982 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2023-01-01 2023-03-31 0001582982 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2023-01-01 2023-03-31 0001582982 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001582982 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001582982 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001582982 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001582982 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-03-31 0001582982 2023-01-01 2023-03-31 0001582982 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2023-04-01 2023-06-30 0001582982 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2023-04-01 2023-06-30 0001582982 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001582982 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001582982 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001582982 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001582982 us-gaap:TreasuryStockCommonMember 2023-04-01 2023-06-30 0001582982 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-01-01 2022-03-31 0001582982 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2022-01-01 2022-03-31 0001582982 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001582982 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001582982 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001582982 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001582982 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-03-31 0001582982 2022-01-01 2022-03-31 0001582982 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-04-01 2022-06-30 0001582982 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2022-04-01 2022-06-30 0001582982 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001582982 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001582982 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001582982 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001582982 us-gaap:TreasuryStockCommonMember 2022-04-01 2022-06-30 0001582982 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2023-06-30 0001582982 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2023-06-30 0001582982 us-gaap:CommonStockMember 2023-06-30 0001582982 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001582982 us-gaap:RetainedEarningsMember 2023-06-30 0001582982 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001582982 us-gaap:TreasuryStockCommonMember 2023-06-30 0001582982 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-06-30 0001582982 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2022-06-30 0001582982 us-gaap:CommonStockMember 2022-06-30 0001582982 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001582982 us-gaap:RetainedEarningsMember 2022-06-30 0001582982 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001582982 us-gaap:TreasuryStockCommonMember 2022-06-30 0001582982 2022-06-30 0001582982 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2023-01-01 2023-06-30 0001582982 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2023-01-01 2023-06-30 0001582982 2023-01-01 0001582982 2022-01-01 2022-12-31 0001582982 CCLD:ContractsAndRelationshipsAcquiredMember 2023-06-30 0001582982 CCLD:ContractsAndRelationshipsAcquiredMember 2022-12-31 0001582982 CCLD:CapitalizedSoftwareMember 2023-06-30 0001582982 CCLD:CapitalizedSoftwareMember 2022-12-31 0001582982 us-gaap:NoncompeteAgreementsMember 2023-06-30 0001582982 us-gaap:NoncompeteAgreementsMember 2022-12-31 0001582982 us-gaap:OtherIntangibleAssetsMember 2023-06-30 0001582982 us-gaap:OtherIntangibleAssetsMember 2022-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-06-30 0001582982 CCLD:UnexercisedWarrantsMember 2023-01-01 2023-06-30 0001582982 srt:MinimumMember 2023-06-30 0001582982 srt:MaximumMember 2023-06-30 0001582982 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-06-30 0001582982 CCLD:UnexercisedWarrantsMember 2022-01-01 2022-06-30 0001582982 CCLD:SVBCreditFacilityMember 2023-06-30 0001582982 CCLD:SVBCreditFacilityMember 2023-02-28 0001582982 CCLD:SVBCreditFacilityMember us-gaap:PrimeRateMember 2023-06-30 0001582982 CCLD:SVBCreditFacilityMember 2023-01-01 2023-06-30 0001582982 CCLD:SVBDebtAgreementMember 2023-01-01 2023-06-30 0001582982 CCLD:SVBDebtAgreementMember 2023-06-30 0001582982 CCLD:SVBDebtAgreementMember 2018-07-01 2018-09-30 0001582982 CCLD:SVBDebtAgreementMember CCLD:AdditionalWarrantMember 2018-09-30 0001582982 CCLD:SVBDebtAgreementMember CCLD:AdditionalWarrantMember 2023-01-01 2023-06-30 0001582982 CCLD:VehicleFinancingNotesMember 2023-01-01 2023-06-30 0001582982 CCLD:InsuranceFinancingMember 2023-06-30 0001582982 CCLD:PhysicianMember 2023-04-01 2023-06-30 0001582982 CCLD:PhysicianMember 2022-04-01 2022-06-30 0001582982 CCLD:PhysicianMember 2023-01-01 2023-06-30 0001582982 CCLD:PhysicianMember 2022-01-01 2022-06-30 0001582982 CCLD:PhysicianMember us-gaap:RelatedPartyMember 2023-06-30 0001582982 CCLD:PhysicianMember us-gaap:RelatedPartyMember 2022-12-31 0001582982 CCLD:ExecutiveChairmanMember 2023-04-01 2023-06-30 0001582982 CCLD:ExecutiveChairmanMember 2022-04-01 2022-06-30 0001582982 CCLD:ExecutiveChairmanMember 2023-01-01 2023-06-30 0001582982 CCLD:ExecutiveChairmanMember 2022-01-01 2022-06-30 0001582982 CCLD:RelatedPartyLeaseMember 2023-06-30 0001582982 CCLD:RelatedPartyLeaseMember 2022-12-31 0001582982 srt:DirectorMember us-gaap:SeriesBPreferredStockMember CCLD:ConsultingAgreementMember 2022-06-01 2022-06-30 0001582982 srt:DirectorMember us-gaap:SeriesBPreferredStockMember CCLD:FebruaryTwoThousandTwentyThreeMember CCLD:ConsultingAgreementMember 2023-02-01 2023-02-28 0001582982 srt:DirectorMember us-gaap:SeriesBPreferredStockMember CCLD:JanuaryTwoThousandTwentyFourMember CCLD:ConsultingAgreementMember 2023-01-01 2023-06-30 0001582982 CCLD:AtTheMarketMember us-gaap:SeriesBPreferredStockMember 2023-01-01 2023-06-30 0001582982 us-gaap:SeriesBPreferredStockMember 2023-01-01 2023-06-30 0001582982 CCLD:AtTheMarketMember us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001582982 us-gaap:SeriesBPreferredStockMember 2022-01-01 2022-06-30 0001582982 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-03-01 2022-03-18 0001582982 us-gaap:SeriesAPreferredStockMember 2022-03-01 2022-03-18 0001582982 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-03-18 0001582982 CCLD:HealthcareITMember CCLD:TechnologyEnabledBusinessSolutionsMember 2023-04-01 2023-06-30 0001582982 CCLD:HealthcareITMember CCLD:TechnologyEnabledBusinessSolutionsMember 2022-04-01 2022-06-30 0001582982 CCLD:HealthcareITMember CCLD:TechnologyEnabledBusinessSolutionsMember 2023-01-01 2023-06-30 0001582982 CCLD:HealthcareITMember CCLD:TechnologyEnabledBusinessSolutionsMember 2022-01-01 2022-06-30 0001582982 CCLD:HealthcareITMember CCLD:ProfessionalServicesMember 2023-04-01 2023-06-30 0001582982 CCLD:HealthcareITMember CCLD:ProfessionalServicesMember 2022-04-01 2022-06-30 0001582982 CCLD:HealthcareITMember CCLD:ProfessionalServicesMember 2023-01-01 2023-06-30 0001582982 CCLD:HealthcareITMember CCLD:ProfessionalServicesMember 2022-01-01 2022-06-30 0001582982 CCLD:HealthcareITMember CCLD:PrintingAndMailingServicesMember 2023-04-01 2023-06-30 0001582982 CCLD:HealthcareITMember CCLD:PrintingAndMailingServicesMember 2022-04-01 2022-06-30 0001582982 CCLD:HealthcareITMember CCLD:PrintingAndMailingServicesMember 2023-01-01 2023-06-30 0001582982 CCLD:HealthcareITMember CCLD:PrintingAndMailingServicesMember 2022-01-01 2022-06-30 0001582982 CCLD:HealthcareITMember CCLD:GroupPurchasingServicesMember 2023-04-01 2023-06-30 0001582982 CCLD:HealthcareITMember CCLD:GroupPurchasingServicesMember 2022-04-01 2022-06-30 0001582982 CCLD:HealthcareITMember CCLD:GroupPurchasingServicesMember 2023-01-01 2023-06-30 0001582982 CCLD:HealthcareITMember CCLD:GroupPurchasingServicesMember 2022-01-01 2022-06-30 0001582982 CCLD:MedicalPracticeManagementMember 2023-04-01 2023-06-30 0001582982 CCLD:MedicalPracticeManagementMember 2022-04-01 2022-06-30 0001582982 CCLD:MedicalPracticeManagementMember 2023-01-01 2023-06-30 0001582982 CCLD:MedicalPracticeManagementMember 2022-01-01 2022-06-30 0001582982 CCLD:DigitalHealthServicesMember 2023-04-01 2023-06-30 0001582982 CCLD:DigitalHealthServicesMember 2023-01-01 2023-06-30 0001582982 CCLD:RevenueCycleManagementandOrionAcquisitionMember 2023-06-30 0001582982 CCLD:OrionAcquisitionMember 2023-01-01 2023-06-30 0001582982 CCLD:OrionAcquisitionMember 2023-06-30 0001582982 us-gaap:TradeAccountsReceivableMember us-gaap:AccountingStandardsUpdate201613Member 2023-01-01 0001582982 CCLD:AmendedAndRestatedEquityIncentivePlanMember us-gaap:CommonStockMember 2022-12-31 0001582982 CCLD:AmendedAndRestatedEquityIncentivePlanMember us-gaap:SeriesBPreferredStockMember 2022-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonStockMember 2023-06-30 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2023-06-30 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonStockMember 2022-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SeriesAPreferredStockMember 2022-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SeriesBPreferredStockMember 2022-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SeriesAPreferredStockMember 2023-01-01 2023-06-30 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SeriesBPreferredStockMember 2023-01-01 2023-06-30 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SeriesAPreferredStockMember 2023-06-30 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SeriesBPreferredStockMember 2023-06-30 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonStockMember 2021-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SeriesAPreferredStockMember 2021-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SeriesBPreferredStockMember 2021-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonStockMember 2022-01-01 2022-06-30 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SeriesAPreferredStockMember 2022-01-01 2022-06-30 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SeriesBPreferredStockMember 2022-01-01 2022-06-30 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonStockMember 2022-06-30 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SeriesAPreferredStockMember 2022-06-30 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SeriesBPreferredStockMember 2022-06-30 0001582982 CCLD:DirectOperatingCostsMember 2023-04-01 2023-06-30 0001582982 CCLD:DirectOperatingCostsMember 2022-04-01 2022-06-30 0001582982 CCLD:DirectOperatingCostsMember 2023-01-01 2023-06-30 0001582982 CCLD:DirectOperatingCostsMember 2022-01-01 2022-06-30 0001582982 us-gaap:GeneralAndAdministrativeExpenseMember 2023-04-01 2023-06-30 0001582982 us-gaap:GeneralAndAdministrativeExpenseMember 2022-04-01 2022-06-30 0001582982 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-06-30 0001582982 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-06-30 0001582982 us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-01 2023-06-30 0001582982 us-gaap:ResearchAndDevelopmentExpenseMember 2022-04-01 2022-06-30 0001582982 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-06-30 0001582982 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-06-30 0001582982 us-gaap:SellingAndMarketingExpenseMember 2023-04-01 2023-06-30 0001582982 us-gaap:SellingAndMarketingExpenseMember 2022-04-01 2022-06-30 0001582982 us-gaap:SellingAndMarketingExpenseMember 2023-01-01 2023-06-30 0001582982 us-gaap:SellingAndMarketingExpenseMember 2022-01-01 2022-06-30 0001582982 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001582982 us-gaap:FairValueInputsLevel3Member 2021-12-31 0001582982 us-gaap:FairValueInputsLevel3Member 2023-01-01 2023-06-30 0001582982 us-gaap:FairValueInputsLevel3Member 2022-01-01 2022-06-30 0001582982 us-gaap:FairValueInputsLevel3Member 2023-06-30 0001582982 us-gaap:FairValueInputsLevel3Member 2022-06-30 0001582982 CCLD:HealthcareITMember 2023-01-01 2023-06-30 0001582982 CCLD:UnallocatedCorporateExpensesMember 2023-01-01 2023-06-30 0001582982 CCLD:HealthcareITMember 2023-04-01 2023-06-30 0001582982 CCLD:UnallocatedCorporateExpensesMember 2023-04-01 2023-06-30 0001582982 CCLD:HealthcareITMember 2022-01-01 2022-06-30 0001582982 CCLD:UnallocatedCorporateExpensesMember 2022-01-01 2022-06-30 0001582982 CCLD:HealthcareITMember 2022-04-01 2022-06-30 0001582982 CCLD:UnallocatedCorporateExpensesMember 2022-04-01 2022-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure CCLD:Segment

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 10-Q

(Mark one)

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended June 30, 2023

 

or

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from to

 

Commission File Number 001-36529

 

 

CareCloud, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   22-3832302
(State or other jurisdiction of   (I.R.S. Employer
incorporation or organization)   Identification Number)

 

7 Clyde Road    
Somerset, New Jersey   08873
(Address of principal executive offices)   (Zip Code)

 

(732) 873-5133

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per share   CCLD   Nasdaq Global Market
11% Series A Cumulative Redeemable Perpetual Preferred Stock, par value $0.001 per share   CCLDP   Nasdaq Global Market
8.75% Series B Cumulative Redeemable Perpetual Preferred Stock, par value $0.001 per share   CCLDO   Nasdaq Global Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer   Accelerated filer
Non-accelerated filer   Smaller reporting company
    Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

 

At July 30, 2023, the registrant had 15,628,097 shares of common stock, par value $0.001 per share, outstanding.

 

 

 

 

 

 

INDEX

 

    Page
Forward-Looking Statements 2
     
PART I. FINANCIAL INFORMATION  
     
Item 1. Consolidated Financial Statements (Unaudited)  
  Consolidated Balance Sheets at June 30, 2023 and December 31, 2022 3
  Consolidated Statements of Operations for the three and six months ended June 30, 2023 and 2022 4
  Consolidated Statements of Comprehensive (Loss) Income for the three and six months ended June 30, 2023 and 2022 5
  Consolidated Statements of Shareholders’ Equity for the three and six months ended June 30, 2023 and 2022 6
  Consolidated Statements of Cash Flows for the six months ended June 30, 2023 and 2022 7
  Notes to Consolidated Financial Statements 8
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 23
Item 3. Quantitative and Qualitative Disclosures about Market Risk 34
Item 4. Controls and Procedures 34
     
PART II. OTHER INFORMATION  
     
Item 1. Legal Proceedings 35
Item 1A. Risk Factors 35
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 35
Item 3. Defaults Upon Senior Securities 35
Item 4. Mine Safety Disclosures 35
Item 5. Other Information 35
Item 6. Exhibits 35
Signatures 36

 

1
 

 

Forward-Looking Statements

 

Certain statements that we make from time to time, including statements contained in this Quarterly Report on Form 10-Q, constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical fact contained in this Quarterly Report on Form 10-Q are forward-looking statements. These statements relate to anticipated future events, future results of operations or future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “might,” “will,” “shall,” “should,” “could,” “intends,” “expects,” “plans,” “goals,” “projects,” “anticipates,” “believes,” “seeks,” “estimates,” “forecasts,” “predicts,” “possible,” “potential,” “target,” or “continue” or the negative of these terms or other comparable terminology. Our operations involve risks and uncertainties, many of which are outside of our control, and any one of which, or a combination of which, could materially affect our results of operations and whether the forward-looking statements ultimately prove to be correct. Forward-looking statements in this Quarterly Report on Form 10-Q include, without limitation, statements reflecting management’s expectations for future financial performance and operating expenditures (including our ability to continue as a going concern, to raise additional capital and to succeed in our future operations), expected growth, profitability and business outlook, increased sales and marketing expenses, and the expected results from the integration of our acquisitions.

 

Forward-looking statements are only predictions, are uncertain and involve substantial known and unknown risks, uncertainties, and other factors that may cause our (or our industry’s) actual results, levels of activity or performance to be materially different from any future results, levels of activity or performance expressed or implied by these forward-looking statements. These factors include, among other things, the unknown risks and uncertainties that we believe could cause actual results to differ from these forward-looking statements as set forth under the heading “Risk Factors” in our Annual Report on Form 10-K filed with the SEC on March 2, 2023. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all of the risks and uncertainties that could have an impact on the forward-looking statements, including without limitation, risks and uncertainties relating to:

 

  our ability to manage our growth, including acquiring, partnering with, and effectively integrating acquired businesses into our infrastructure and avoiding legal exposure and liabilities associated with acquired companies and assets;
     
  our ability to retain our clients and revenue levels, including effectively migrating new clients and maintaining or growing the revenue levels of our new and existing clients;
     
  our ability to maintain operations in our offshore offices in a manner that continues to enable us to offer competitively priced products and services;
     
  our ability to keep pace with a rapidly changing healthcare industry;
     
  our ability to consistently achieve and maintain compliance with a myriad of federal, state, foreign, local, payor and industry requirements, regulations, rules, laws and contracts;
     
  our ability to maintain and protect the privacy of confidential and protected Company, client and patient information;
     
  our ability to develop new technologies, upgrade and adapt legacy and acquired technologies to work with evolving industry standards and third-party software platforms and technologies, and protect and enforce all of these and other intellectual property rights;
     
  our ability to attract and retain key officers and employees, and the continued involvement of Mahmud Haq as Executive Chairman and A. Hadi Chaudhry as Chief Executive Officer and President, all of which are critical to our ongoing operations, growing our business and integrating of our newly acquired businesses;
     
  our ability to comply with covenants contained in our credit agreement with our senior secured lender, Silicon Valley Bank, a division of First-Citizens Bank & Trust Company, and other future debt facilities;
     
  our ability to pay our monthly preferred dividends to the holders of our Series A and Series B preferred stock;
     
  our ability to compete with other companies developing products and selling services competitive with ours, and who may have greater resources and name recognition than we have;
     
  our ability to respond to the uncertainty resulting from the ongoing COVID-19 pandemic and the impact it may have on our operations, the demand for our services, our projected results of operations, financial performance or other financial metrics or any of the foregoing risks and economic activity in general;
     
  our ability to keep and increase market acceptance of our products and services;
     
  changes in domestic and foreign business, market, financial, political and legal conditions; and
     
  other factors disclosed in this Quarterly Report on Form 10-Q or our other filings with the Securities and Exchange Commission (the “SEC”).

 

The forward-looking statements contained in this Quarterly Report on Form 10-Q are based on our current expectations, beliefs and views as of the date of this Quarterly Report on Form 10-Q concerning future developments and their potential effects on our business. Although we believe that the expectations reflected in the forward-looking statements contained in this Quarterly Report on Form 10-Q are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. We anticipate that subsequent events and developments may cause our assessments to change. Except as required by law, we are under no duty to update or revise any of such forward-looking statements, whether as a result of new information, future events, or otherwise, after the date of this Quarterly Report on Form 10-Q.

 

You should read this Quarterly Report on Form 10-Q with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we currently expect. The forward-looking statements contained herein should not be relied upon as representing our assessments as of any date subsequent to the date of this Quarterly Report on Form 10-Q.

 

2
 

 

PART I. FINANCIAL INFORMATION

Item 1. Consolidated Financial Statements

CARECLOUD, INC.

CONSOLIDATED BALANCE SHEETS

($ in thousands, except share and per share amounts)

 

 

   June 30,   December 31, 
   2023   2022 
   (Unaudited)     
ASSETS          
Current assets:          
Cash  $7,666   $12,299 
Accounts receivable - net   12,018    14,773 
Contract asset   4,834    4,399 
Inventory   402    381 
Current assets - related party   16    16 
Prepaid expenses and other current assets   2,880    2,785 
Total current assets   27,816    34,653 
Property and equipment - net   4,747    5,056 
Operating lease right-of-use assets   4,427    4,921 
Intangible assets - net   27,923    29,520 
Goodwill   61,186    61,186 
Other assets   737    838 
TOTAL ASSETS  $126,836   $136,174 
LIABILITIES AND SHAREHOLDERS’ EQUITY          
Current liabilities:          
Accounts payable  $5,179   $5,681 
Accrued compensation   3,147    4,248 
Accrued expenses   3,933    4,432 
Operating lease liability (current portion)   1,986    2,273 
Deferred revenue (current portion)   1,242    1,386 
Notes payable (current portion)   5    319 
Dividend payable   4,120    4,059 
Total current liabilities   19,612    22,398 
Notes payable   11    13 
Borrowings under line of credit   10,000    8,000 
Operating lease liability   2,731    3,207 
Deferred revenue   370    342 
Deferred tax liability   589    525 
Total liabilities   33,313    34,485 
COMMITMENTS AND CONTINGENCIES (NOTE 7)   -    - 
SHAREHOLDERS’ EQUITY:          
Preferred stock, $0.001 par value - authorized 7,000,000 shares. Series A, issued and outstanding 4,526,231 shares at June 30, 2023 and December 31, 2022. Series B, issued and outstanding 1,454,392 and 1,344,128 shares at June 30, 2023 and December 31, 2022, respectively   6    6 
Common stock, $0.001 par value - authorized 35,000,000 shares. Issued 16,368,896 and 15,970,204 shares at June 30, 2023 and December 31, 2022, respectively. Outstanding 15,628,097 and 15,229,405 shares at June 30, 2023 and December 31, 2022, respectively   16    16 
Additional paid-in capital   126,857    130,987 
Accumulated deficit   (28,040)   (25,621)
Accumulated other comprehensive loss   (4,654)   (3,037)
Less: 740,799 common shares held in treasury, at cost at June 30, 2023 and December 31, 2022   (662)   (662)
Total shareholders’ equity   93,523    101,689 
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY  $126,836   $136,174 

 

See notes to consolidated financial statements.

 

3
 

 

CARECLOUD, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

($ in thousands, except share and per share amounts)

 

 

   2023   2022   2023   2022 
   Three Months Ended   Six Months Ended 
   June 30,   June 30, 
   2023   2022   2023   2022 
NET REVENUE  $29,362   $37,228   $59,363   $72,569 
OPERATING EXPENSES:                    
Direct operating costs   17,476    21,787    35,583    44,460 
Selling and marketing   2,580    2,426    5,192    4,810 
General and administrative   5,916    6,394    11,036    11,979 
Research and development   1,185    1,098    2,263    2,083 
Change in contingent consideration   -    (630)   -    (1,230)
Depreciation and amortization   3,341    2,936    6,379    5,876 
Net loss on lease terminations and unoccupied lease charges   153    463    422    621 
Total operating expenses   30,651    34,474    60,875    68,599 
OPERATING (LOSS) INCOME   (1,289)   2,754    (1,512)   3,970 
OTHER:                    
Interest income   52    3    72    8 
Interest expense   (327)   (107)   (477)   (207)
Other (expense) income - net   (186)   112    (169)   195 
(LOSS) INCOME BEFORE PROVISION FOR INCOME TAXES   (1,750)   2,762    (2,086)   3,966 
Income tax provision   82    25    147    89 
NET (LOSS) INCOME  $(1,832)  $2,737   $(2,233)  $3,877 
                     
Preferred stock dividend   3,910    3,776    7,841    7,813 
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS  $(5,742)  $(1,039)  $(10,074)  $(3,936)
                     
Net loss per common share: basic and diluted  $(0.37)  $(0.07)  $(0.65)  $(0.26)
Weighted-average common shares used to compute basic and diluted loss per share   15,615,760    15,070,147    15,518,965    15,031,363 

 

See notes to consolidated financial statements.

 

4
 

 

CARECLOUD, INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME (UNAUDITED)

($ in thousands)

 

 

   2023   2022   2023   2022 
   Three Months Ended   Six Months Ended 
   June 30,   June 30, 
   2023   2022   2023   2022 
NET (LOSS) INCOME  $(1,832)  $2,737   $(2,233)  $3,877 
OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX                    
Foreign currency translation adjustment (a)  94    (990)   (1,617)   (1,245)
COMPREHENSIVE (LOSS) INCOME  $(1,738)  $1,747   $(3,850)  $2,632 

 

(a)No tax effect has been recorded as the Company recorded a valuation allowance against the tax benefit from its foreign currency translation adjustments.

 

See notes to consolidated financial statements.

 

5
 

 

CARECLOUD, INC.

CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY (UNAUDITED)

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2023 AND JUNE 30, 2022

($ in thousands, except for number of shares)

 

 

   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Deficit   Loss   Stock   Equity 
  

Preferred Stock

Series A

  

Preferred Stock

Series B

   Common Stock  

Additional

Paid-in

   Accumulated  

Accumulated

Other

Comprehensive

  

Treasury

(Common)

  

Total

Shareholders’

 
   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Deficit   Loss   Stock   Equity 
Balance - January 1, 2023 before adoption of ASC 326   4,526,231   $5    1,344,128   $1    15,970,204   $16   $130,987   $(25,621)  $(3,037)  $(662)  $101,689 
Cumulative effect of adopting ASC 326   -    -    -    -    -    -    -    (186)   -    -    (186)
Balance - January 1, 2023 after adoption   4,526,231    5    1,344,128    1    15,970,204    16    130,987    (25,807)   (3,037)   (662)   101,503 
Net loss   -    -    -    -    -    -    -    (401)   -    -    (401)
Foreign currency translation adjustment   -    -    -    -    -    -    -    -    (1,711)   -    (1,711)
Issuance of stock under the equity incentive plan   -    -    41,491    -    343,203    -    -    -    -    -    - 
Stock-based compensation, net of cash settlements   -    -    -    -    -    -    1,185    -    -    -    1,185 
Shares issued for services   -    -    -    -    20,000    -    -    -    -    -    - 
Issuance of Series B Preferred Stock   -    -    59,773    -    -    -    1,437    -    -    -    1,437 
Preferred stock dividends   -    -    -    -    -    -    (3,931)   -    -    -    (3,931)
Balance - March 31, 2023   4,526,231   $5    1,445,392   $1    16,333,407   $16   $129,678   $(26,208)  $(4,748)  $(662)  $98,082 
                                                        
Balance - April 1, 2023   4,526,231   $5    1,445,392   $1    16,333,407   $16   $129,678   $(26,208)  $(4,748)  $(662)  $98,082 
Net loss   -    -    -    -    -    -    -    (1,832)   -    -    (1,832)
Foreign currency translation adjustment   -    -    -    -    -    -    -    -    94    -    94 
Issuance of stock under the equity incentive plan   -    -    9,000    -    15,489    -    -    -    -    -    - 
Stock-based compensation, net of cash settlements   -    -    -    -    -    -    1,089    -    -    -    1,089 
Shares issued for services   -    -    -    -    20,000    -    -    -    -    -    - 
Preferred stock dividends   -    -    -    -    -    -    (3,910)   -    -    -    (3,910)
Balance - June 30, 2023   4,526,231   $5    1,454,392   $1    16,368,896   $16   $126,857   $(28,040)  $(4,654)  $(662)  $93,523 
                                                        
Balance - January 1, 2022   5,299,227   $5    -   $-    15,657,641   $16   $131,379   $(31,053)  $(1,754)  $(662)  $97,931 
Net income   -    -    -    -    -    -    -    1,140    -    -    1,140 
Foreign currency translation adjustment   -    -    -    -    -    -    -    -    (255)   -    (255)
Issuance of stock under the equity incentive plan   22,319    -    -    -    145,809    -    -    -    -    -    - 
Stock-based compensation, net of cash settlements   -    -    -    -    -    -    887    -    -    -    887 
Redemption of Series A Preferred Stock   (800,000)   -    -    -    -    -    (20,000)   -    -    -    (20,000)
Issuance of Series B Preferred Stock   -    -    1,150,372    1    -    -    26,637    -    -    -    26,638 
Stock issuance costs   -    -    -    -    -    -    (11)   -    -    -    (11)
Preferred stock dividends   -    -    -    -    -    -    (4,037)   -    -    -    (4,037)
Balance - March 31, 2022   4,521,546   $5    1,150,372   $1    15,803,450   $16   $134,855   $(29,913)  $(2,009)  $(662)  $102,293 
                                                        
Balance - April 1, 2022   4,521,546   $5    1,150,372   $1    15,803,450   $16   $134,855   $(29,913)  $(2,009)  $(662)  $102,293 
Net income   -    -    -    -    -    -    -    2,737    -    -    2,737 
Foreign currency translation adjustment   -    -    -    -    -    -    -    -    (990)   -    (990)
Issuance of stock under the equity incentive plan   4,685    -    10,000    -    15,809    -    -    -    -    -    - 
Stock-based compensation, net of cash settlements   -    -    -    -    -    -    1,257    -    -    -    1,257 
Redemption of Series A Preferred Stock   -    -    -    -    -    -    (5)   -    -    -    (5)
Issuance of Series B Preferred Stock   -    -    49,876    -    -    -    1,223    -    -    -    1,223 
Stock issuance costs   -    -    -    -    -    -    (10)   -    -    -    (10)
Preferred stock dividends   -    -    -    -    -    -    (3,776)   -    -    -    (3,776)
Balance - June 30, 2022   4,526,231   $         5    1,210,248   $         1    15,819,259   $    16   $  133,544   $(27,176)  $(2,999)  $(662)  $102,729 

 

For all periods presented, the preferred stock dividends were paid monthly at the rate of $2.75 and $2.19 for Series A and Series B, respectively, per share per annum.

 

See notes to consolidated financial statements.

 

6
 

 

CARECLOUD, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

FOR THE SIX MONTHS ENDED JUNE 30, 2023 AND 2022

($ in thousands)

 

 

   2023   2022 
OPERATING ACTIVITIES:          
Net (loss) income  $(2,233)  $3,877 
Adjustments to reconcile net (loss) income to net cash provided by operating activities:          
Depreciation and amortization   6,663    6,159 
Lease amortization   1,153    1,658 
Deferred revenue   (116)   387 
Provision for doubtful accounts   302    580 
Provision for deferred income taxes   64    28 
Foreign exchange loss (gain)   176    (159)
Interest accretion   325    323 
Gain on sale of assets   -    (6)
Stock-based compensation expense   2,574    2,071 
Change in contingent consideration   -    (1,230)
Changes in operating assets and liabilities:          
Accounts receivable   2,267    (2,558)
Contract asset   (435)   25 
Inventory   (21)   127 
Other assets   (318)   (264)
Accounts payable and other liabilities   (2,993)   (2,892)
Net cash provided by operating activities   7,408    8,126 
INVESTING ACTIVITIES:          
Purchases of property and equipment   (1,621)   (973)
Capitalized software   (4,456)   (4,654)
Net cash used in investing activities   (6,077)   (5,627)
FINANCING ACTIVITIES:          
Preferred stock dividends paid   (7,780)   (7,683)
Settlement of tax withholding obligations on stock issued to employees   (1,166)   (910)
Repayments of notes payable   (316)   (338)
Stock issuance costs   -    (21)
Proceeds from issuance of Series B Preferred Stock, net of expenses   1,437    27,860 
Redemption of Series A Preferred Stock   -    (20,005)
Proceeds from line of credit   12,700    17,500 
Repayment of line of credit   (10,700)   (18,500)
Net cash used in financing activities   (5,825)   (2,097)
EFFECT OF EXCHANGE RATE CHANGES ON CASH   (139)   (522)
NET DECREASE IN CASH AND RESTRICTED CASH   (4,633)   (120)
CASH AND RESTRICTED CASH - Beginning of the period   12,299    10,340 
CASH AND RESTRICTED CASH - End of the period  $7,666   $10,220 
SUPPLEMENTAL NONCASH INVESTING AND FINANCING ACTIVITIES:          
Dividends declared, not paid  $4,120   $3,986 
SUPPLEMENTAL INFORMATION - Cash paid during the period for:          
Income taxes  $111   $128 
Interest  $341   $93 

 

See notes to consolidated financial statements.

 

7
 

 

CARECLOUD, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AS OF AND FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2023

AND 2022 (UNAUDITED)

 

1. ORGANIZATION AND BUSINESS

 

CareCloud, Inc., (together with its consolidated subsidiaries, “CareCloud,” the “Company,” “we,” “us” and/or “our”) is a leading provider of technology-enabled services and solutions that redefine the healthcare revenue cycle. We provide technology-enabled revenue cycle management and a full suite of proprietary cloud-based solutions to healthcare providers, from small practices to enterprise medical groups, hospitals, and health systems throughout the United States. Healthcare organizations today operate in highly complex and regulated environments. Our suite of technology-enabled solutions helps our clients increase financial and operational performance, streamline clinical workflows, and improve the patient experience.

 

Our portfolio of proprietary software and business services includes: technology-enabled business solutions that maximize revenue cycle management and create efficiencies through platform agnostic AI-driven applications; cloud-based software that helps providers manage their practice and patient engagement while leveraging analytics to improve provider performance; digital health services to address value-based care and enable the delivery of remote patient care; healthcare IT professional services & staffing to address physician burnout, staffing shortages and leverage consulting expertise to transition into the next generation of healthcare; and, medical practice management services to assist medical providers with operating models and the tools needed to run their practice.

 

Our high-value business services, such as revenue cycle management, are often paired with our cloud-based software, premiere healthcare consulting and implementation services, and on-demand workforce staffing capabilities for high-performance medical groups and health systems nationwide.

 

CareCloud has its corporate office in Somerset, New Jersey and maintains client support teams throughout the U.S., and offshore offices in Pakistan and Azad Jammu and Kashmir, a region administered by Pakistan (the “Pakistan Offices”), and in Sri Lanka. During the second quarter of 2023, the Company formed a wholly owned subsidiary, CareCloud ME Health Consultancy LLC, in the United Arab Emirates, which has not yet begun operations.

 

2. BASIS OF PRESENTATION AND SUMMARY OF SIGINIFICANT ACCOUNTING POLICIES

 

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and as required by Regulation S-X, Rule 8-03. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of the Company’s management, the accompanying unaudited consolidated financial statements contain all adjustments (consisting of items of a normal and recurring nature) necessary to present fairly the Company’s financial position as of June 30, 2023, the results of operations for the three and six months ended June 30, 2023 and 2022 and cash flows for the six months ended June 30, 2023 and 2022. When preparing financial statements in conformity with GAAP, the Company must make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ significantly from those estimates. The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

 

The accompanying unaudited consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2022, which are included in the Company’s Annual Report on Form 10-K, filed with the SEC on March 2, 2023.

 

Significant Accounting Policies — During the six months ended June 30, 2023, there were no changes to the Company’s significant accounting policies, other than the adoption of ASU 2016-13 discussed below, from its disclosures in the Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 2, 2023.

 

8
 

 

Recent Accounting Pronouncements — From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) and are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently adopted and recently issued accounting pronouncements will not have a material impact on our consolidated financial position, results of operations and cash flows.

 

In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses: Measurement of Credit Losses on Financial Instruments. The guidance in Accounting Standards Update (“ASU”) 2016-13 replaces the incurred loss impairment methodology under current GAAP. The new impairment model requires immediate recognition of estimated credit losses expected to occur for most financial assets and certain other instruments. It will apply to all entities. For trade receivables, loans and held-to-maturity debt securities, entities will be required to estimate lifetime expected credit losses. This may result in the earlier recognition of credit losses. In November 2019, the FASB issued ASU No. 2019-10, which delays this standard’s effective date for SEC smaller reporting companies to the fiscal years beginning on or after December 15, 2022. The Company adopted this guidance on January 1, 2023 using a modified retrospective adoption methodology, whereby the cumulative impact of all prior periods is recorded in accumulated deficit or other impacted balance sheet items upon adoption. The impact to the accumulated deficit as of January 1, 2023 for the allowance related to accounts receivable was a charge of approximately $186,000 and a corresponding increase to the allowance for doubtful accounts.

 

In March 2023, the FASB issued ASU 2023-01, Leases (Topic 842): Common Control Arrangements – Issue 2. The amendments in this update require that leasehold improvements associated with common control leases be: (1) amortized by the lessee over the useful life of the leasehold improvements to the common control group as long as the lessee controls the use of the underlying asset through a lease and (2) accounted for as a transfer between entities under common control through an adjustment to equity if, and when, the lessee no longer controls the use of the underlying asset. The amendments in this update are effective for fiscal years beginning after December 15, 2023. The Company does not expect this update to have a material impact on the consolidated financial statements.

 

3. GOODWILL AND INTANGIBLE ASSETS-NET

 

The following is the summary of the carrying amount of goodwill for the six months ended June 30, 2023 and the year ended December 31, 2022:

  

           
   Six Months Ended   Year Ended 
  

June 30, 2023

  

December 31, 2022

 
   ($ in thousands) 
Beginning gross balance  $61,186   $61,186 
Acquisitions   -    - 
Ending gross balance  $61,186   $61,186 

 

Intangible assets – net as of June 30, 2023 and December 31, 2022 consist of the following:

  

           
   June 30, 2023   December 31, 2022 
   ($ in thousands) 
Contracts and relationships acquired  $47,597   $47,597 
Capitalized software   25,165    21,547 
Non-compete agreements   1,236    1,236 
Other intangible assets   8,417    8,415 
Total intangible assets   82,415    78,795 
Less: Accumulated amortization   54,492    49,275 
Intangible assets - net  $27,923   $29,520 

 

9
 

 

Capitalized software represents payroll and development costs incurred for internally developed software. Other intangible assets primarily represent purchased intangibles. Amortization expense was approximately $5.4 million and $4.9 million for the six months ended June 30, 2023 and 2022. The weighted-average amortization period is three years.

 

As of June 30, 2023, future amortization scheduled to be expensed is as follows:

  

Years ending December 31,  

($ in thousands)

 
2023 (six months)   $7,180 
2024    10,237 
2025    6,992 
2026    2,464 
2027    300 
Thereafter    750 
Total   $27,923 

 

4. NET LOSS PER COMMON SHARE

 

The following table reconciles the weighted-average shares outstanding for basic and diluted net loss per share for the three and six months ended June 30, 2023 and 2022:

  

                     
   Three Months Ended June 30,   Six Months Ended June 30, 
   2023   2022   2023   2022 
   ($ in thousands, except share and per share amounts) 
Basic and Diluted:                    
Net loss attributable to common shareholders  $(5,742)  $(1,039)  $(10,074)  $(3,936)
Weighted-average common shares used to compute basic and diluted loss per share   15,615,760    15,070,147    15,518,965    15,031,363 
Net loss attributable to common shareholders per share - basic and diluted  $(0.37)  $(0.07)  $(0.65)  $(0.26)

 

At June 30, 2023, the 605,689 unvested equity restricted stock units (“RSUs”) as discussed in Note 11 and 128,489 unexercised warrants expiring between July 2023 and September 2023 with exercise prices between $5.00 to $5.26 have been excluded from the above calculations as they were anti-dilutive. At June 30, 2022, the 433,251 unvested equity RSUs and 1,353,489 unexercised warrants have been excluded from the above calculations as they were anti-dilutive. Vested RSUs, vested restricted shares and exercised warrants have been included in the above calculations.

 

5. DEBT

 

Bank Debt —The Company has a revolving line of credit with Silicon Valley Bank (“SVB”). The Company’s credit facility is a secured revolving line of credit where borrowings are based on a formula of 200% of repeatable revenue adjusted by an annualized attrition rate as defined in the credit agreement. During February 2023, the line of credit was increased to $25 million and the term was extended for two additional years. The financial covenants were also slightly modified for 2023 and subsequent years.

 

As of June 30, 2023 and December 31, 2022, there was $10 million and $8 million, respectively, of borrowings under the credit facility. Interest on the revolving line of credit is currently charged at the prime rate plus 1.50%. There is also a fee of one-half of 1% annually for the unused portion of the credit line. The debt is secured by all of the Company’s domestic assets and 65% of the shares in its offshore subsidiaries. Future acquisitions are subject to approval by SVB.

 

10
 

 

In connection with the original SVB debt agreement, the Company paid SVB approximately $50,000 of fees upfront and issued warrants for SVB to purchase 125,000 shares of its common stock, and committed to pay an annual anniversary fee of $50,000 a year. Based on the terms in the original SVB credit agreement, these warrants had a strike price equal to $3.92. They had a five years exercise window and net exercise rights, and were valued at $3.12 per warrant. These warrants were exercised during 2022. As a result of the revision in the credit line in the third quarter of 2018, the Company paid approximately $50,000 of fees upfront and issued an additional 28,489 warrants, with a strike price equal to $5.26, a five-year exercise window and net exercise rights. The additional warrants were valued at $3.58 per warrant and expire in September 2023. The credit agreement contains various covenants and conditions governing the revolving line of credit including a current annual fee of $100,000. These covenants include a minimum level of adjusted EBITDA and a minimum liquidity ratio. At June 30, 2023 and December 31, 2022, the Company was in compliance with all covenants.

 

During March 2023, SVB became a division of First-Citizens Bank & Trust Company. The agreements that governed the former SVB relationship remain in place. There was no change to the terms of the credit agreement.

 

The Company maintains cash balances at SVB in excess of the FDIC insurance coverage limits. The Company performs periodic evaluations of the relative credit standing of this financial institution to ensure its credit worthiness. As of June 30, 2023 and December 31, 2022, the Company held cash of approximately $75,000 and $1.8 million, respectively, in the name of its subsidiaries at banks in Pakistan and Sri Lanka. The banking systems in these countries do not provide deposit insurance coverage. The Company has not experienced any losses on its cash accounts.

 

Vehicle Financing Notes — The Company financed certain vehicle purchases in the United States. The vehicle financing notes have six year terms and were issued at current market rates.

 

Insurance Financing — The Company finances certain insurance purchases over the term of the policy life. The interest rate charged is currently 4.55%.

 

6. LEASES

 

We determine if an arrangement is a lease at inception. We have operating leases for office and temporary living space as well as for some office equipment. Operating leases are included in operating lease right-of-use (“ROU”) assets, current operating lease liability and non-current operating lease liability in our consolidated balance sheets as of June 30, 2023 and December 31, 2022. The Company does not have any finance leases.

 

As most of our leases do not provide an implicit rate, we use our estimated incremental borrowing rates, which are derived from information available at the lease commencement date, in determining the present value of lease payments. We give consideration to our bank financing arrangements, geographical location and collateralization of assets when calculating our incremental borrowing rates. We review our incremental borrowing rate on a quarterly basis.

 

Our lease terms include options to extend the lease when we believe that we may want the right to exercise that option. Leases with a term of less than 12 months are not recorded in the consolidated balance sheets. Our lease agreements do not contain any residual value guarantees. For real estate leases, we account for the lease and non-lease components as a single lease component. Some leases include escalation clauses and termination options that are factored in the determination of the lease payments when appropriate.

 

If a lease is modified after the effective date, the operating lease ROU asset and liability are re-measured using the current incremental borrowing rate. During the three and six months ended June 30, 2023, there were approximately $11,000 and $163,000, respectively, of unoccupied lease charges for two of the Company’s facilities. During the three and six months ended June 30, 2022, there were approximately $266,000 and $529,000, respectively, of unoccupied lease charges. During the six months ended June 30, 2022, there was a gain on lease termination of approximately $105,000.

 

11
 

 

During the six months ended June 30, 2023, the Miami office lease that we assumed in connection with an acquisition ended, and we entered into a new lease arrangement with the landlord for significantly less office space. Charges of approximately $71,000 were incurred as a result of vacating the former premises. During the three months ended June 30, 2022, a facility lease was terminated in conjunction with the Company ceasing its document storage services resulting in additional costs of approximately $197,000. This termination of lease resulted in additional costs for the three and six months ended June 30, 2023, of approximately $115,000 and $161,000, respectively. In addition, during the three months ended June 30, 2023, the Company paid approximately $27,000 to settle a claim regarding a lease termination in India. These amounts are included in net loss on lease terminations and unoccupied lease charges in the consolidated statements of operations.

 

Lease expense is included in direct operating costs, general and administrative expense, selling and marketing expense and research and development expense in the consolidated statements of operations based on the nature of the expense. Our lease terms are determined taking into account lease renewal options, the Company’s anticipated operating plans and leases that are on a month-to-month basis. The Company also has some related party leases – see Note 8.

 

The components of lease expense were as follows:

 

   2023   2022   2023   2022 
  

Three Months Ended June 30,

  

Six Months Ended June 30,

 
   2023   2022   2023   2022 
   ($ in thousands) 
Operating lease cost  $598   $905   $1,399   $1,877 
Short-term lease cost   -    35    -    75 
Variable lease cost   14    10    19    19 
Total - net lease cost  $612   $950   $1,418   $1,971 

 

Short-term lease cost represents leases that were not capitalized as the lease term as of the later of January 1, 2023 or the beginning of the lease was less than 12 months. Variable lease costs include utilities, real estate taxes and common area maintenance costs.

 

Supplemental balance sheet information related to leases is as follows:

 

  

June 30, 2023

  

December 31, 2022

 
   ($ in thousands) 
Operating leases:          
Operating lease ROU assets, net  $4,427   $4,921 
           
Current operating lease liabilities  $1,986   $2,273 
Non-current operating lease liabilities   2,731    3,207 
Total operating lease liabilities  $4,717   $5,480 
           
Operating leases:          
ROU assets  $5,640   $8,293 
Asset lease expense   (1,153)   (3,286)
Foreign exchange loss   (60)   (86)
ROU assets, net  $4,427   $4,921 
           
Weighted average remaining lease term (in years):          
Operating leases   4.3    5.1 
Weighted average discount rate:          
Operating leases   12.3%   7.9%

 

12
 

 

Supplemental cash flow and other information related to leases is as follows:

 

   2023   2022   2023   2022 
   Three Months Ended June 30,   Six Months Ended June 30, 
   2023   2022   2023   2022 
   ($ in thousands) 
Cash paid for amounts included in the measurement of lease liabilities: